The Neglected Tropical Disease Treatment Market Size is valued at USD 2.9 billion in 2023 and is predicted to reach USD 4.4 billion by the year 2031 at a 5.3% CAGR during the forecast period for 2024-2031.
Neglected tropical disease treatment describes medical approaches and activities, such as medication, vaccinations, and public health campaigns, that are intended to address infectious diseases that largely impact underprivileged communities in tropical countries. The market for neglected tropical disease treatment products is being propelled forward by the increasing frequency of these diseases in developing nations due to several factors, including poor hygiene and a lack of access to necessary services like clean water. Additionally, the continuous investments made by pharmaceutical companies in research and development play a major role in the expansion of the industry. Moreover, the market for treating neglected tropical diseases depends on infrastructure upgrades. Improving medical facilities facilitates more efficient service delivery, expands access to therapies, and aids in continuing disease control and surveillance initiatives, all of which will enhance overall market growth in the coming years.
However, the high cost of treatment, lack of expertise, and poor healthcare infrastructure are slowing down the market growth. Additionally, the COVID-19 epidemic delayed diagnosis and treatment initiatives, therefore distorting the neglected tropical disease treatment market by redirecting healthcare resources and attention. However, strong health systems and faster developments in telemedicine and healthcare delivery are needed. In addition, there is rising growth in the healthcare sector, rising government incentives, and more investment in the neglected tropical disease treatment market.
The neglected tropical disease treatment market is segmented based on drug class, disease type, distribution channel. As per the drug class, the market is classified into anti-parasite, antifungal, antibiotics, and others. By disease type, the market is segmented into leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. The distribution channel segment comprises direct sales and indirect sales.
Antibiotics in the neglected tropical disease treatment market are expected to hold a major global market share in 2023 because of their essential part in preventing bacterial infections connected to these disorders. Demand is driven in part by growing awareness of drug-resistant strains and more healthcare campaigns to fight these diseases. Furthermore, enhancing antibiotic accessibility and efficacy is a continuous research and development initiative that is driving this market growth.
The leishmaniasis segment is growing rapidly because of the growing worldwide travel and migration that help the disease spread. Additionally, higher detection rates are the result of growing knowledge and better diagnosis methods. Moreover, improved government and non-governmental support for research and control initiatives is accelerating the development and implementation of successful treatments, therefore stimulating expansion in this market sector.
The Asia Pacific neglected tropical disease treatment market is expected to note the highest revenue share in the near future. This can be attributed to large investments in research and development, excellent healthcare infrastructure, strong government support for disease elimination, and heightened public health awareness. In addition, North America is projected to grow very fast in the neglected tropical disease treatment market because of growing healthcare expenditures, higher disease prevalence, more treatment accessibility, and more government projects aiming at disease control innovation in healthcare technology.
Recent Developments:
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.9 Bn |
|
Revenue Forecast In 2031 |
USD 4.4 Bn |
|
Growth Rate CAGR |
CAGR of 5.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug Class, Disease Type, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Omega Diagnostics Group PLC, Abbott, Oscar Medicare Pvt Ltd., Genome Diagnostics Pvt. Ltd., ZeptoMetrix and Other market players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neglected Tropical Disease Treatment Market Snapshot
Chapter 4. Global Neglected Tropical Disease Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Neglected Tropical Disease Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Neglected Tropical Disease Treatment Industry Trends
Chapter 5. Neglected Tropical Disease Treatment Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. Anti-Parasite
5.2.2. Antifungal
5.2.3. Antibiotics
5.2.4. Others
Chapter 6. Neglected Tropical Disease Treatment Market Segmentation 2: By Disease Type, Estimates & Trend Analysis
6.1. Market Share by Disease Type, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Disease Types:
6.2.1. Leishmaniasis
6.2.2. Schistosomiasis
6.2.3. Lymphatic Filariasis
6.2.4. Chagas Disease
6.2.5. African Trypanosomiasis
6.2.6. Others
Chapter 7. Neglected Tropical Disease Treatment Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
7.2.1. Direct Sales
7.2.2. Indirect Sales
Chapter 8. Neglected Tropical Disease Treatment Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. Global Neglected Tropical Disease Treatment Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.2.3. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.2.4. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.3. Europe
8.3.1. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.3.3. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.3.4. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.4.3. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.4.4. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
8.5. Latin America
8.5.1. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.5.3. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.5.4. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
8.6.3. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031
8.6.4. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Thermo Fisher Scientific, Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. F. Hoffmann-La Roche Ltd.
9.2.3. Omega Diagnostics Group PLC
9.2.4. Abbott
9.2.5. Oscar Medicare Pvt. Ltd.
9.2.6. Merck Ltd.
9.2.7. Genome Diagnostics Pvt. Ltd.
9.2.8. ZeptoMetrix
9.2.9. Bayer AG,
9.2.10. GlaxoSmithKline plc
9.2.11. Novartis AG
9.2.12. Pfizer, Inc.
9.2.13. Eisai Co. Ltd.
9.2.14. Sanofi
9.2.15. Astellas Pharma
9.2.16. Takeda Pharmaceutical Company Limited
9.2.17. Gilead Sciences
9.2.18. Other Market Players
Neglected Tropical Disease Treatment Market By Drug Class-
Neglected Tropical Disease Treatment Market By Disease Type-
Neglected Tropical Disease Treatment Market By Distribution Channel-
Neglected Tropical Disease Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
